<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788007</url>
  </required_header>
  <id_info>
    <org_study_id>IMQC 1220</org_study_id>
    <nct_id>NCT01788007</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative efficacy and safety of the test
      formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod)
      3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference
      formulations will also be compared to a placebo cream to test for superiority.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success</measure>
    <time_frame>Week 14 (8 weeks after completion of treatment)</time_frame>
    <description>Treatment success will be defined by the proportion of patients in the per protocol population with 100% clearance of all actinic keratosis lesions within the treatment area at study week 14 (8 weeks after completion of treatment.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Superiority to placebo</measure>
    <time_frame>Week 14 (8 weeks after completion of treatment)</time_frame>
    <description>The modified intent-to-treat population and last observation carried forward will be used to evaluate the superiority of both the test and reference product to placebo for the proportion of patients showing 100% clearance of actinic keratosis lesions at week 14 (8 weeks after completion of treatment.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">443</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Imiquimod Topical Cream 3.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Topical Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zyclara® (imiquimod) Topical Cream 3.75%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Topical Cream 3.75%</intervention_name>
    <description>Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Imiquimod Topical Cream 3.75%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyclara® (imiquimod) Topical Cream 3.75%</intervention_name>
    <description>Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Zyclara® (imiquimod) Topical Cream 3.75%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Topical Cream</intervention_name>
    <description>Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.</description>
    <arm_group_label>Vehicle Topical Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.

          -  Diagnosis of actinic keratosis with at least 5 and no more than 20 clinically typical,
             visible or palpable actinic keratosis lesions, each at least 4 mm in diameter, in an
             area that exceeds 25 cm2 on either the face (excluding ear) or balding scalp (but not
             both.)

          -  Women either must be 1 year post-menopausal, surgically sterile, or if they are of
             child-bearing potential, they must: a) have been using systemic birth control,
             intrauterine device, or Norplant for at least 28 days prior to the start of treatment
             period, or used barrier methods consistently, at least 14 days before study cream
             administration; b) had a normal menstrual cycle for the month prior to the start of
             treatment; c) have a negative urine pregnancy test result upon entry into the study;
             d) agree to use a medically accepted form of birth control throughout the study
             period.

          -  Free from any systemic or dermatologic disorder that, in the opinion of the
             Investigator, will interfere with the study results or increase the risk of adverse
             events.

          -  Any skin type or race, providing the skin pigmentation will allow discernment of
             erythema.

          -  Willingness and capability to cooperate to the extent and degree required by the
             protocol.

        Exclusion Criteria:

          -  Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema,
             psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face
             or bald scalp.

          -  Use within six months prior to baseline on the face or bald scalp of chemical peel,
             dermabrasion, laser abrasion, psoralen plus ultraviolet A therapy, or ultra violet B
             therapy.

          -  Use within one month prior to baseline on the face or bald scalp of cryodestruction or
             chemodestruction, curettage, photodynamic therapy, surgical excision, topical
             5-fluorouracil, topical corticosteroids, topical diclofenac, topical imiquimod,
             topical retinoids or other treatments for actinic keratosis including glycolic acids
             or over-the-counter products containing retinol, alpha or beta hydroxy acids.

          -  Use within one month prior to baseline of immunomodulators or immunosuppressive
             therapies, interferon, oral corticosteroids or cytotoxic drugs.

          -  Known allergies to imiquimod or any excipients to the test or reference creams.

          -  Receiving 5-fluorouracil or other systemic cancer chemotherapy within 6 months prior
             to study entry.

          -  Any condition, medical, psychological, or social, that, in the Investigator's opinion,
             would interfere with participation in the study.

          -  Women who are pregnant or planning pregnancy or lactating during the study.

          -  Participation in any investigational drug study within 30 days of enrollment or
             previous participation in this study.

          -  Employees or family members of employees of the research center or Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Imiquimod Topical Cream 3.75%</keyword>
  <keyword>Zyclara® (imiquimod) Topical Cream 3.75%</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

